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Resumo 
 
 
 
Terapia fágica, resistência a antibióticos, bactérias patogénicas, Escherichia coli, infeções 
urinárias. 
 
Escherichia coli é uma bactéria oportunista que pode ser encontrada como parte da flora 
normal do trato gastrointestinal humano e de alguns mamíferos. Este microrganismo é 
capaz de provocar diversas infeções, sendo responsável pela maioria das infeções do trato 
urinário (ITU). E. coli é resistente a uma grande variedade de antibióticos, tornando difícil 
o tratamento de infeções por ela causadas. Deste modo, a terapia fágica pode ser uma 
ferramenta útil no tratamento de infeções causadas por estirpes de E. coli resistentes aos 
antibióticos. Contudo, também a terapia fágica também leva ao desenvolvimento de 
bactérias mutantes resistentes aos fagos. Por esta razão, neste trabalho, foi avaliada a 
combinação de duas terapias, quimioterapia e terapia fágica, de modo a avaliar possíveis 
efeitos sinérgicos e atenuar o desenvolvimento de resistências aos fagos e antibióticos. 
Foi usado o fago ECA2, isolado num estudo prévio, e vários antibioticos (ampicilina, 
canamicina, piperacilina, ciprofloxacina tetraciclina e cloranfenicol) com diferentes 
mecanismos de ação. A estirpe de E. coli usada é sensível aos antibióticos ciprofloxacina, 
tetraciclina e cloranfenicol e resistente aos antibióticos ampicilina, canamicina e 
piperacilina. O fago ECA2 inativou eficientemente a bactéria E. coli, causando uma 
redução de ≈4,5 log na concentração da bactéria após 2 horas de tratamento em phosphate 
buffered saline (PBS). A inativação bacteriana com a mistura de fago e antibióticos 
ampicilina, canamicina e piperacilina foram similares aos resultados obtidos apenas com 
o fago. Como a estirpe bacteriana apresentava resistência a estes antibióticos, a inativação 
bacteriana resultante foi devida apenas à ação do fago. As misturas do fago ECA2 com 
cloranfenicol e com tetraciclina mostraram ser menos eficazes na inativação da bactéria 
do que o fago sozinho. A conjugação do fago com a ciprofloxacina resultou numa 
inativação bacteriana de cerca de 8,3 log, em detrimento dos ≈ 4,5 log de inativação 
bacteriana obtidos com apenas o fago. Além disso, a conjugação do fago ECA2 com a 
ciprofloxacina resultam numa diminuição das resistências bacterianas obtidas em relação 
ao fago e ao antibiótico individualmente. A terapia fágica também foi avaliada em urina 
com vista a avaliar o uso desta terapia no controlo de infeções urinárias. A inativação de 
E. coli na urina foi semelhante à obtida nos ensaios em PBS, tanto para o fago como para 
a conjugação do fago ECA2 com a ciprofloxacina. Foi ainda testado na urina um cocktail 
com dois fagos, o fago ECA2 e com outro fago específico para esta bactéria, o fagophT4A 
(previamente isolado pelo grupo de trabalho). Observou-se numa redução bacteriana de 
3,5 log. Os resultados indicam que a combinação fagos e antibióticos pode resultar num 
efeito sinérgico na inativação de bactérias, mas apenas quando a bactéria é sensível ao 
antibiótico. Além disso, a combinação de antibióticos com fagos contribui para a gestão 
dos níveis de resistência, controlando a resistência aos antibióticos e os mutantes 
resistentes ao fago. Os fagos limitam o desenvolvimento de variantes resistentes a 
antibióticos em tratamentos combinados independentemente do tipo de antibiótico, mas 
os antibióticos limitam a resistência de mutantes aos fagos apenas quando as bactérias 
são sensíveis ao antibiótico. Contudo, em geral, na presença de antibióticos, a resistência 
dos mutantes aos fagos foi a mesma ou menor do que quando os fagos foram testados 
isoladamente. A elevada eficiência de inativação bacteriana por fagos combinada com 
uma maior inativação bacteriana na presença de antibiótico, e a elevada sobrevivência 
dos fagos em urina, abre o caminho para estudos mais aprofundados para controlar a UTI 
e o desenvolvimento de resistências em E. coli, a bactéria mais frequentemente isolada 
em UTI ao nível da comunidade e em ambientes hospitalares. 
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Abstract 
 
 
 
Escherichia coli is part of the normal flora of the gastrointestinal tract of humans and 
various mammals. This opportunistic microorganism is capable of cause several 
infections, such as urinary tract infections (UTI). E. coli is resistant to a large number of 
antibiotics, becoming harder the control of infections caused by this bacterium. Phage 
therapy may be a useful tool to control infections caused by antibiotic resistant strains. 
However, the major concern of the phage therapy is also the emergence of phage resistant 
bacteria. In this study, was evaluated the combination of two different therapies, 
chemotherapy and phage therapy, to evaluate the possibility of synergic effects between 
them. It was used the phage ECA2 (a phage previously isolated by the research group) 
and various antibiotics (ampicillin, kanamycin, piperacillin, tetracycline, 
chloramphenicol and ciprofloxacin) with different mechanisms of action. The E. coli 
strain used in this study is sensitive to the antibiotics ciprofloxacin, tetracycline and 
chloramphenicol and resistant to the antibiotics ampicillin, kanamycin and piperacillin 
The phage ECA2 caused a reduction in E. coli concentration of ≈ 4.5 log after 2 hours of 
treatment in phosphate buffered saline (PBS). The results obtained with the mixtures of 
the phage with ampicillin, kanamycin and piperacillin did not cause significantly 
differences when compared with the results obtained just with the phage. As the 
bacterium E. coli showed resistance to those antibiotics, the bacterial inactivation was 
just due the action of the phage. Otherwise, the results obtained using the mixtures of 
ECA2 with tetracycline and chloramphenicol were worse than the results obtained just 
with the phage. The conjugation of the phage with ciprofloxacin resulted in a bacterial 
inactivation of about 8.3 log, compared to the ≈4.5 log of bacterial inactivation obtained 
with the phage alone. In addition, the conjugation of the phage ECA2 with ciprofloxacin 
resulted in a decrease of the bacterial resistances obtained the phage and the antibiotic 
individually. The efficacy of phage therapy in urine was also evaluated, with the phage 
and the mix of phage and ciprofloxacin. The inactivation of E. coli in urine samples was 
similar to that obtained in PBS. It was observed a decrease of 4.3 log after 4 hours of 
treatment. Furthermore, a cocktail with two phages, the phage ECA2 and another E. coli 
specific phage, previously isolated by the research group, the phage phT4A, was also 
tested. The E. coli inactivation was 3.5 log after 4 hours. The results indicate that phage 
and antibiotic combinations could result in synergistic effect in the inactivation of 
bacteria, but only when the bacterium is sensitive to the antibiotic. Also, the combination 
of antibiotics with phages contributes to managing resistance levels, controlling the 
antibiotic resistance and phage-resistant mutants. The phages limit the emergence of 
antibiotic resistant variants in combined treatments independently of antibiotic type, but 
the antibiotics limit the resistance of phage-mutants only when bacteria are sensitive to 
the antibiotic. However, overall, in the presence of antibiotics the resistance of phage-
mutants was the same or less than when phages were tested alone. The high bacterial 
inactivation efficiency with phages combined with a higher bacterial inactivation in the 
presence of antibiotic and the long periods of phage survival in urine samples, paves the 
way for depth studies to control urinary tract infection and to overcome the development 
of resistances by E. coli, the bacterium most frequently isolated in UTI at the community 
level and at hospital settings 
 
Table of Contents 
List of Acronyms and Abbreviations ............................................................................................... i 
List of Tables .....................................................................................................................................ii 
List of Figures ................................................................................................................................... iii 
Chapter 1- General Introduction ..................................................................................................... 3 
1.1. Escherichia coli ................................................................................................................. 4 
1.2. Urinary Tract Infections .................................................................................................. 5 
1.3. Bacteriophages .................................................................................................................. 6 
1.3.1. Bacteriophage morphology ...................................................................................... 6 
1.3.2. Taxonomy of bacteriophages ................................................................................... 8 
1.3.3. Life cycle of bacteriophages..................................................................................... 9 
1.4. Phage Therapy ................................................................................................................ 11 
1.4.1. Phage seleccion ....................................................................................................... 11 
1.4.2. Multiplicity of infection ......................................................................................... 12 
1.4.3. Advantages and disadvantages of phage therapy ................................................ 12 
1.5. Antibacterial therapy ..................................................................................................... 14 
1.5.1. Mechanism of action of antibiotics ....................................................................... 14 
1.5.2. Antibacterial resistance to antibiotics .................................................................. 17 
1.5.3. Escherichia coli genes of resistance to antibiotics ................................................ 20 
Chapter 2- Potential effects of bacteriophages and antibiotics to inactivate Escherichia coli .. 21 
2.1. Introduction .................................................................................................................... 22 
2.2. Materials and methods ................................................................................................... 24 
2.2.1. Bacterial strain and growth conditions ................................................................ 24 
2.2.2. Phage selection and quantification ....................................................................... 24 
2.2.3. Bacterial kill curves in PBS ................................................................................... 25 
2.2.4. Bacterial kill curves with phage and antibiotics in PBS ..................................... 25 
2.2.5. Antimicrobial Susceptibility Tests ........................................................................ 26 
2.2.6. Determination of the rate of emergence of phage-resistant bacteria ................. 26 
2.2.7. Determination of catalase and indol activity ....................................................... 28 
2.2.8. Bacterial kill curves in Urine ................................................................................. 28 
2.2.9. Statistical analysis .................................................................................................. 29 
2.3. Results ............................................................................................................................. 30 
 2.3.1. Kill curves in PBS ................................................................................................... 30 
2.3.2. Antibiotic test susceptibility .................................................................................. 31 
2.3.3. Kill curves in PBS with antibiotic ......................................................................... 31 
2.3.3.1. Ampicillin ................................................................................................................ 31 
2.3.3.2. Kanamycin .............................................................................................................. 33 
2.3.3.3. Piperacillin .............................................................................................................. 34 
2.3.3.4. Tetracycline............................................................................................................. 35 
2.3.3.5. Chloramphenicol .................................................................................................... 36 
2.3.4. Kill curves in Urine ................................................................................................ 39 
2.3.5. Kill curves with ciprofloxacin in Urine ................................................................ 40 
2.3.6. Determination of the emergence of bacterial mutants ........................................ 42 
2.3.7. Growth of bacterial resistant mutants .................................................................. 43 
2.3.8. Physiological characteristics of E. coli before and after phage treatment. ....... 44 
2.4. Discussion ........................................................................................................................ 45 
2.5. Future perpectives .......................................................................................................... 51 
Chapter 3 - References ................................................................................................................... 52 
i 
 
List of Acronyms and Abbreviations 
ANOVA Analysis of variance 
CFU Colony forming units 
DHF Dihydrofolate 
DNA Deoxyribonucleic acid 
ds Double-stranded 
EUCAST European Committee on Antimicrobial Susceptibility Testing 
G Gravitacional force 
ICTV The International Committee on Taxonomy of Viruses 
log Logarithm 
LPS Lipopolysaccharide 
MIC Minimum Inhibitory Concentration 
MOI Multiplicity of infection 
mRNA Messenger ribonucleic acid 
ºC Degrees Celsius 
PABA Para-aminobenzoic acid 
PBP Penicillin-Binding-Proteins 
PBS Phosphate-Buffered Saline 
PFU Plaque forming units 
PFU/mL Plaque forming units per milliliter 
rRNA Ribosome ribonucleic acid 
ss Sigle-stranded 
THF Tetrahydrofolic acid 
tRNA Transfer ribonucleic acid 
TSA Tryptone Soy Agar 
TSB Tryptone Soy Broth 
UTI Urinary tract infection 
WHO Word Health Organization 
ii 
 
List of Tables 
Table 1: Major characteristics of phage families (adaptated from  Ackermann 2007) ..................... 8 
Table 3: Major genes responsible for antibiotic resistances in strains of E. coli............................. 20 
Table  3: Antibiotic test susceptibility to Escherichia coli ATCC 13706 ....................................... 31 
Table 4: Frequency of mutants of Escherichia coli ATCC 13706 to the phage ECA2, antibibiotics 
and to the conjugation of both. ......................................................................................................... 42 
iii 
 
List of Figures 
Figure 1: Schematic representation of characteristics and outer membrane antigens [3] ................. 4 
Figure 2: Representation of a typical bacteriophage [18] ................................................................. 7 
Figure 3: General phage life cycle (Adapted from Weinbauer, 2004) ............................................ 10 
Figure 4: Classification of antibiotics by mechanism of action (Li, Collins, and Keene 2015) ...... 15 
Figure 5: Horizontal gene transfer between bacteria (adapted from Furuya 2006) ........................ 19 
Figure 6: Diagram representing the major machanisms of antibiotic resistance (Vranakis 2013) . 19 
Figure 7: Design of the experimental work to test the emergence of bacterial resistances {adapted 
from (Haddix 2000) and (Filipov 2011) ........................................................................................... 27 
Figure 8: Inactivation of E. coli with phage ECA2 in PBS during 8 hours. (A)- Bacterial 
concentration: BC- bacterial control; B+P- bacteria plus phage. (B)- Phage concentration: PC-
phage control; B+P bacteria plus phage. .......................................................................................... 30 
Figure 9: Results of the Antibiotic Susceptibility test of the bacteria E. coli ATCC 13706. .......... 31 
Figure 10:  Inactivation of E. coli with phage ECA2 and Ampicillin (MIC of 32 mg/L) in PBS 
during 8 hours. (A)- Bacterial concentration: BC- bacterial control AC- Antibiotic control; B+P- 
bacteria plus phage, B+P+A- bacteria plus phage plus antibiotic. (B)- Phage concentration: PC-
phage control; B+P bacteria plus phage; B+P+A- bacteria plus phage plus antibiotic. ................... 32 
Figure 11: Inactivation of E. coli with phage ECA2 and Kanamycin (MIC of 32 mg/L) in PBS 
during 8 hours. (A)- Bacterial concentration: BC- bacterial control AC- Antibiotic control; B+P- 
bacteria plus phage, B+P+A- bacteria plus phage plus antibiotic. (B)- Phage concentration: PC-
phage control; B+P bacteria plus phage; B+P+A- bacteria plus phage plus antibiotic. ................... 33 
Figure 12: Inactivation of E. coli with phage ECA2 and Piperacillin (MIC of 16 mg/L) in PBS 
during 8 hours. (A)- Bacterial concentration: BC- bacterial control AC- Antibiotic control; B+P- 
bacteria plus phage, B+P+A- bacteria plus phage plus antibiotic. (B)- Phage concentration: PC-
phage control; B+P bacteria plus phage; B+P+A- bacteria plus phage plus antibiotic. ................... 34 
Figure 13: Inactivation of E. coli with phage ECA2 and Tetracycline (MIC of 4 mg/L) in PBS 
during 8 hours. (A)- Bacterial concentration: BC- bacterial control AC- Antibiotic control; B+P- 
bacteria plus phage, B+P+A- bacteria plus phage plus antibiotic. (B)- Phage concentration: PC-
phage control; B+P bacteria plus phage; B+P+A- bacteria plus phage plus antibiotic .................... 35 
Figure 14: Inactivation of E. coli with phage ECA2 and Chloramphenicol (MIC of 8 mg/L) in PBS 
during 8 hours. (A)- Bacterial concentration: BC- bacterial control AC- Antibiotic control; B+P- 
bacteria plus phage, B+P+A- bacteria plus phage plus antibiotic. (B)- Phage concentration: PC-
phage control; B+P bacteria plus phage; B+P+A- bacteria plus phage plus antibiotic. ................... 36 
Figure 15: Inactivation of E. coli with phage ECA2 and Ciprofloxacin (MIC of 0.05 mg/L) in PBS 
during 8 hours. (A)- Bacterial concentration: BC- bacterial control AC- Antibiotic control; B+P- 
bacteria plus phage, B+P+A- bacteria plus phage plus antibiotic. (B)- Phage concentration: PC-
phage control; B+P bacteria plus phage; B+P+A- bacteria plus phage plus antibiotic. ................... 38 
Figure 16: Inactivation of E. coli with phage ECA2 and Ciprofloxacin (MIC of 0.5 mg/L) in PBS 
during 120 min. (A)- Bacterial concentration: BC- bacterial control AC- Antibiotic control; B+P- 
bacteria plus phage, B+P+A- bacteria plus phage plus antibiotic. (B)- Phage concentration: PC-
phage control; B+P bacteria plus phage; B+P+A- bacteria plus phage plus antibiotic. ................... 39 
Figure 17: Inactivation of E. coli with phage ECA2 and the cocktail of two phages ECA2/T4 in 
human urine during 8 hours. (A)- Bacterial concentration: BC- bacterial control; B+ECA2- bacteria 
plus phage ECA2, B+(ECA2/T4)- bacteria plus cocktail (ECA27T4). (B)- Phage concentration: C 
ECA2-phage control; C(ECA2/T4)- cocktail control;  B+ECA2 bacteria plus phage ECA2; 
B+(ECA2/T4)- bacteria plus phage cocktail .................................................................................... 40 
iv 
 
Figure 18: Inactivation of E. coli with phage ECA2 and Ciprofloxacin (MIC of 0.05 mg/L) in 
Urine during 8 hours. (A)- Bacterial concentration: BC- bacterial control AC- Antibiotic control; 
B+P- bacteria plus phage, B+P+A- bacteria plus phage plus antibiotic. (B)- Phage concentration: 
PC-phage control; B+P bacteria plus phage; B+P+A- bacteria plus phage plus antibiotic. ............. 41 
Figure 19: Bacterial concentration of resistant mutants to phage, antibiotics and the misture of 
phage and antibiotic and of sensitive bacteria during 96 h of incubation. ....................................... 44 
 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thesis outline and objectives 
  
2 
 
Objectives and Thesis Outline 
 This present work foccuses in the utilization of phage therapy combined with 
antibiotics to inactivate E. coli. This bacterium is responsible for many urinary tract 
infections and it is resistant to most antibiotics used worldwide.  
This document has two chapters. Chapter 1 includes a literature review, serving as a 
basis for the following experimental work. The Chapter 2 includes an experimental work 
about the efficiency of phage therapy in the control of E. coli growth, in order to assess the 
suitability of phage therapy in the treatment of urinary tract infections. It was also tested the 
possibility of a synergic effect between bacteriophages and antibiotics with clinical use, 
focusing on the emergence of resistances to both antibiotic and phages.   
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Chapter 1- General Introduction
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1.1. Escherichia coli 
Escherichia coli belongs to the Enterobacteriaceae family, which is the largest and 
most heterogeneous family of gram-negative bacilli. The primary difference between Gram-
positive and Gram-negative focuses on the cell wall [1]. 
E. coli is a nonspore-forming bacteria with motility due its peritrichous flagella and it 
is a bacteria with fimbriae. Most E. coli strains are capable of growing over a large range of 
temperature (approximately 15 – 48 °C). The growth rate is maximal in the narrow range of 
37 – 42 °C [2]. 
This bacterium is facultative anaerobe, capable to reduce nitrates to nitrites. Also, it is 
capable of fermenting glicose with gas production and capable of produce catalase. E. coli 
is positive for indole production and the methyl red test. Most strains are oxidase, citrate, 
urease and hydrogen sulfide negative. The ability of E. coli to ferment lactose is a classic 
differencial test to separate this species from Shigella and Salmonella [2].  
 
Figure 1: Schematic representation of characteristics and outer membrane antigens [3] 
 
This bacterium can be found at the commensal flora of the intestinal tract of humans 
and many other animals. E. coli is one of the most frequent causes of common bacterial 
infections, including intra-abdominal like cholecystitis and cholangitis. It also cause enteric 
infections, like traveler diarrhea [4]. 
E. coli is the bacteria most implied urinary tract infections (UTI), including 
uncomplicated urethritis/cystitis, symptomatic cystitis pyelonephritis, acute prostatitis, 
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prostatic abscess, and urosepsis. It is also responsible for other clinical infections such as 
pneumonia and meningitis [4]. 
 
1.2. Urinary Tract Infections 
 
The bladder is typically sterile, but the epithelial cells coating the urethra, downstream, 
are colonized by rods and aerobic facultative gram-negative cocci. The presence of 
microorganisms in the terminal urethra, and its multiplication and invasion of tissues can 
cause the beginning of a UTI (urinary tract infections). Although the urinary tract is 
traditionally considered to be sterile, advances in metagenomics and other technologies 
allowed the discovery of a ‘urinary microbiome’, which may alter the way in which we think 
about UTI[4]. 
UTI can be classified in two types, infections acquired in the community, between non 
hospitalized people and nosocomial infections that affect hospitalized patients in health 
institutions.   
The most prevalent microorganisms are aerobic gram-negative. Escherichia coli is the 
prevailing bacterium in both UTI types, being responsible to 75 to 90% of acute UTI in the 
community and around 50 to 60% in the hospital infections, with significant morbility and 
mortality wordwide[5]. Strains of Staphylococcus, Proteus, Klebsiella pneumoniae, 
Pseudomonas, Enterococcus and Enterobacter can also be found as responsible of the UTI 
[6,7].  
There are many factors implicated in the occurrence of UTI such as urinary stasis, 
pregnancy, diabetes, urinary obstruction, poor hygiene, the insertion of foreign objects, 
menopause, neurological disorders and sexual diseases[8]. Females have higher incidence 
in UTI due to the anatomical structure of the female urethra. The female urethra is shorter 
and close to anus than the male urethra, so it is easier for women to commonly have an UTI 
[9,10]. 
The bacterial growth may be promoted by the presence of certain nutrients, such as 
glucose, amino acids and uric acid in urine and by an increase in its pH. The presence of 105 
CFU/mL of the same organism in a sample of urine is defined by significant bacteriuria. The 
main symptoms of a urinary tract infection are numbered as dysuria, increase of urinary 
frequency, burning urinate sensation, fetid urine odor, color changing, difficulty to urinate, 
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presence of blood in urine, pain in the abdomen, fever, chills, back pain, nausea and 
vomit[11].  
The empiric treatment for UTI is the use of broad-spectrum antibiotic and the 
recommended oral antibiotic options include fluoroquinolones, aminopenicillines and 
aminoglycosides[12]. Multidrug resistant E. coli are widely distributed in hospitals and 
actually an increase of this bacterium in the community is observed. E. coli is found to have 
high resistance to several antibiotics, such as aminoglycosides (e.g. Kanamycin, 
Streptomycin, Gentamicin), aminopenicillin (e.g. Ampicillin), sulfonamides, tetracycline 
and fluoroquinolones[13]. 
 
 
1.3. Bacteriophages 
Bacteriophages, or phages, are viruses that infect only prokaryotes (bacteria and 
archaea)[14], resulting usually in propagative lyses (lytic cycle) or lysogenization (lysogenic 
cycle) of the infected cell. Bacteriophages are the most abundant microorganisms at 
biosphere [16-19]. 
Although phages can have two different life cycles, the lytic phages are the best 
candidates for phage therapy because they replicate fast within their hosts and lyse them[15]. 
These biological entities can be defined as a capsid-encoding organism that is composed by 
proteins and nucleic acids, self-assembled in a nucleocapsid that needs a prokaryotic 
organism to completing its life cycle[16,17]. 
The main role of phages in biological ecosystem aims the coevolution of phages with 
their host bacteria and provides the earth ecological equilibrium in several environmental or 
ecological niches[22,23,25]. The most of the phages are tailed phages, which accounts for 
96% of all phages present on earth, belonging to the order Caudovirales (families 
Myoviridae, Siphoviridae and Podoviridae)[18]. 
 
1.3.1. Bacteriophage morphology 
Bacteriophages feature a variety of morphological types, like various shapes ant 
sizes, but generally most have a capsid, a colar and a tail Figure 2[18]. They are essentially 
constituted by two main components: nucleic acids and proteins. 
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Some constituents of bacteriophage have a specific terminology, as is the case of 
nucleic acid that is called core, envelope which is called capsid and the morphological 
subunits holds the name of capsomeres. Also viral infectious particle has a specific 
nomenclature, being called virion[19]. 
The core of phages is encapsulated with a protein or a lipoprotein capsid, that usually 
is the shape of an icosahedron, is connected with a tail that interacts with various bacterial 
surface receptors via the tip of the tail fibers. 
The capsid has three important functions during the phage life cycle: (1) protect the 
phage genome during its extracellular phase, (2) enable the adsorption of the phage, 
fixing the virus to the host bacterium (in Caudovirales), and (3) the subsequent delivery 
of the phage genome into the host cytoplasm[20].  
Usually phages have a size between between 24 and 200 nm long and can vary 
between 17kb and 5000 kb. Its genome can also be very diversified, so can be found 
phages with double-stranded DNA, single-stranded DNA, or single stranded RNA[14]. 
The tail may or may not be a contractile structure bounded to six fibres, that contain 
receptors on their end that are capable of recognize binding sites on the surface of the 
host cell. Nevertheless, not all phages have tail fibers, so in these cases the organism has 
other attachment mechanisms [18,20]. 
 
 
Figure 2: Representation of a typical bacteriophage [18] 
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1.3.2. Taxonomy of bacteriophages 
The International Committee on Taxonomy of Viruses (ICTV) is the responsable for the 
classification of viruses. That classification is based on morphological, like size and shape, 
and molecular characteristics, type of nucleic acid Table 1 [14].  
Nowadays, it can be found around 13 families and 30 genera, belonging to the 
Caudovirales order. Three major families are divided based on tail structure: 
1. Myoviridae- viruses have a contractile tail constituted by hem, a central tube and a 
big capsid head (150 nm); 
2. Siphoviridae- viruses have long not contractible tails, and a relativelly small capsid 
head (50-60nm); 
3. Podoviridae- viruses have no contractile tail and have short tails and a small capsid 
head (50-60 nm). 
The non-tailed phages are classified into ten families and they are polyhedral, 
filamentous or pleomorphic [18,21–23]. 
Table 1: Major characteristics of phage families (adaptated from  Ackermann 2007) 
Shape  Nucleic acid Family name Characteristics 
 
Tailed 
DNA, 2, L Myoviridae Contractil tail 
DNA, 2, L Siphoviridae Long non-contractil tail 
DNA, 2, L Podoviridae Short non-contractil tail 
 
 
Polyhedral 
DNA, 1, C Microviridae Icosahedral capsid 
DNA   2, C, S Corticoviridae Complex capsid with lipid layer 
DNA  2, L Tectiviridae Icosahedral capsid with inner lipid vesicles 
RNA, 1, L Leviviridae Quasi-icosahedral capsid 
 RNA  2,L, seg Cystoviridae Icosahedral capsid, lipids 
Filamentous DNA 1, C Inoviridae Rod-shaped with helical symmetry 
DNA 2, L Lipothrixviridae Enveloped filaments, lipids 
DNA 2, L Rudiviridae Helical rods 
Pleomorfic DNA 1,C,S 
           
Plasmaviridae Envelope, lipids, no capsid.  
 DNA 2,C,S Fuselloviridae Envelope, lipids, no capsid. 
C-Circular; S-superhelical; seg-segmented; 1-single-stranded; 2- double-stranded 
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1.3.3. Life cycle of bacteriophages 
 Bacteriophages are metabolically inert in their extra cellular form. They are only able 
to self-reproduce as long as the host bacteria is present and their replication depends 
exclusively on the host intracellular machinery to translate their own genetic code. 
 Bacteriophages can have one of two major and distinctive types of life cycle, the lytic 
or virulent cycle, the temperate or lysogenic cycle and more sporadically through 
pseudolysogeny. According to this, phages are classified, based on their life cycle, as lytic 
(virulent) or lysogenic (temperate) [17,24]. 
 Lytic phages infect prokaryotic cells, causing inhibition of host metabolism and 
subverting it to the production of phage offspring. The lytic cycle results in the lysis of the 
bacterium accompanied by the release of new multiple phage particles. The new phages 
produced by the host bacteria spread to infect other cells. First, the phage binds to specific 
receptors of bacteria, this phase is called adsorption [17,25]. Phages can use different parts 
of lipopolysaccharide (LPS), flagella, fimbriae and many other surface proteins as receptors. 
Bacteriophages may also use enzymes to break down the bacterial surface[14,26]. Then the 
phage genome is injected into the host bacterium and occurs early gene expression. Most of 
the proteins produced in this phase are involved in the shutting down of the host bacterial 
systems and phage genome replication[25]. After replication of the phage genome, occurs 
the expression of the phage late proteins that are involved in the formation of new phage 
particles and lysis of host bacteria[27]. The phage head and tail are assembled and the phage 
genome is packaged. The bacteria are destroyed through lysis, resulting in a realease of the 
new phage particles. 
 On the other hand, in lisogenic cycle, the phage genome is integrated into the host 
cell DNA. Prophage DNA will be replicated when the host cell genome replicates and so 
daughter cells will inherit the viral DNA (Figure 3). The prophage can stay in a dormant state 
for long periods of time and may become activated and turn on the lytic cycle. The lytic 
cycle is induced spontaneously by chemical or physical agents such as radiation, pollutants, 
changes in temperature and nutrient concentrations[25,28]. At the end the newly formed 
phage particles will lyse the host cell. Lysogeny might be a viral survival strategy to ensure 
periods of low host density during nutrient starvation [25,29]. 
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The life cycle and the genome of many temperate phage is already studied and there is 
evidence that several phages have genetic sequences that induce the production of virulence 
factors in bacteria, so the use of temperate phages in human therapy is inappropriate. Since 
virulent phages do not provide prophage state and therefore do not have or transfers genes 
coding for the production of virulence factors in their hosts[30]. 
Over the two main life cycles of bacteriophages, it is possible to find another 
phenomenon known as pseudolysogeny. Yet, unlike true lysogeny, the phage genome does 
not integrate to the host. Pseudolysogeny is a condition in which the bacterial cells coexists 
with the viruses Figure 3. In the host cells, there is insuficiente energy available for the phage 
initiate genetic expression leading to a temperate or lytic response[31]. When the nutrientes 
are supplied to the bacteria, the pseudolysogens evolve into one of the two phage life cycle, 
lytic or lysogenic. The frequency of pseudolysogen phages is correlated with the 
concentration of nutrientes available to their host[25,31]. 
 
Figure 3: General phage life cycle (Adapted from Weinbauer, 2004) 
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1.4. Phage Therapy 
Phages therapy consists in the utilization of bacteriophages to inactivate pathogenic 
bacteria. Soon after its discovery by Twort in 1915 and d'Herelle in 1917, in which the latter 
named this type of virus, phages soon began to be exploited and used to control infections 
by pathogenic bacteria[25,32]. This method of treatment was used to treat and prevent 
bacterial infections in the former Soviet Union and Eastern Europe, however, was abandoned 
by the west due to the appearance of antibiotics[33].  
Antibiotic use increased rapidly. The mastery of production of antibiotics, the 
relatively broad spectrum of action of antibiotics, and the stability of the preparations were 
advantages over phages, but the emergence of pathogenic bacteria resistant to antibiotics has 
recently teased the western scientific community to reevaluate phage therapy as an option 
for bacterial infections treatment[30,33]. 
 
1.4.1. Phage seleccion 
The selection of appropriate phages is a critical factor to the success of the phage therapy 
as a successful phage-mediated control of pathogenic bacteria. Beside the efficiency on 
bacterial inactivation, it is necessary to have atention to other important characteristics when 
selecting viruses for phage therapy [14,28]. 
 Therapeutic phages should have a very abroad host range, that means that a single 
phage should be virulent to various strains of bacteria[34,35]. The selection of phages with 
a large host range limits the number of phages in the library and also reduces the cost for 
clinical trials[35].  
 The phages used in phage therapy should be characterized in detail. It is importante 
to sequence the genome of the phage, to identify its structure, test its behavior in vitro, and 
to prove their efficiency in vivo [14]. For phage therapy, lytic phages should be elected and 
the development of lysogeny must be avoided. When lysogeny is established the host 
becomes immune to an infection caused by the same or similar phages [36]. Additionally, 
lysogenic phages may transfer genes potentially dangerous between hosts, such as genes that 
encode toxins or virulence factors, which may be toxic to humans[14,32,37]. 
The adsortion is an important phase in the phage infective process to the host cell. 
Studies on T-even (like T2 and T4) and T-odd (like T1 and T3) phages have reveled that a 
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number of environmental factors, such as, ion concentrations, organic cofactors, pH and 
temperature, may have a substantial impact in the adsorpion of the phage to its host cell[38]. 
The increased of the adsorption efficiency had a similar effect to increasing the initial 
multiplicity of infection. It can be observed a decresing of the number of phages during 
amplification [38]. 
The phage burst size (number of phages produced by each host cell) and the latent 
period (time spent from virus entry into the cell until the first offspring are released) are also 
important factors to consider when phages are selected. Selecting phages with high burst 
size (i.e. producing a large number of descendents) is very important. Phages cannot be 
administered in high doses because they dessiminate badly. Wherefore, a high burst size 
increases the probability that phages reach target bacteria, which is crucial for achieving an 
efficient viral infection. If phages can eliminate bacteria faster than they can replicate, a high 
burst size also results in a lower risk of selection for phage resistant bacteria[35]. 
 
1.4.2. Multiplicity of infection 
The most adequate multiplicity of infection (MOI), number of viruses used per host cell, 
to be used in phage therapy is yet a controversial aspect. It has been stated that, contrarily to 
the case of chemicals and other substances, precise initial doses may not be essential in 
treatment, because of the selfperpetuating nature of phages, revealed by an increasing of 
phage titers along with bacteria. The MOI has been mentioned as an important factor 
influencing the efficiency of phage therapy differs among the various animals used for in 
vivo experiments, particulary due to the physical-chemical complex environment and host 
defenses, but differing from the results obtained in vitro[39,40]. 
 
1.4.3. Advantages and disadvantages of phage therapy 
Nowadays, most pathogenic bacteria are resistant to several antibiotics, becoming 
imperative the development of alternative antibacterial alternatives. Nowadays, western 
countries revived the interest in phage therapy [32]. 
Phage therapy is a potential alternative to antibiotics and to other antibacterial 
compounds to inactivate pathogenic bacteria [28]. The major advantages of bacteriophages 
over antibiotics include: 
 13 
 
1) The specificity to the host, since the remaining microbiota is not affected, which is 
an advantage relatively to other antibiotics that can provoke damage in the microbiota 
[41,42]. That characteristic is due the fact that phages only infect a few bacterial 
strains [36]. 
2) Low-cost and rapid production of phage suspensions; 
3) Self-replication, meaning that low or single dosages will multiply as long as there is 
still a host present; 
4) Co-evolution of phage and bacteria result in a fitness cost to the host. 
5) Although some phage-resistant mutants appeared after treatment, it is comparably 
easier to find new phages because phages coevolve with their host bacteria, 
outnumbering bacteria in the environment, what makes possible the rapid isolation 
of new lytic phages from the environment for phage-resistant bacterial mutants. So, 
even if the bacteria acquire phage resistance, new mutant phage that acts lytically 
against these bacteria can be used against the targeted bacteria[43,44]. 
It is safe the use of phage due the fact that no serious side effects have been described, 
because phages or their products (amino acids and nucleic acids) do not affect eukaryotic 
cells [51, 52]. 
Although phage therapy have many advantages, also have some limitations. 
The release of bacterial endotoxins bound to the membrane during cell lysis can cause 
side effects, though, purification of the phage suspensions is a simple process [45]. 
Also, the lysogenic conversion can be another problem associated to this therapy. The 
lysogeny can induce a phenotype modification of the host cell such as toxin production and 
antibiotic resistance but also resistance to infection by similar phages [14,37]. The phage 
infection starts with the attachment of the phage into specific receptors of bacteria. If occurs 
a mutation on the bacteria receptors, the phage fails to recognize bacteria. Despite this 
obstacle to the application of phage therapy, the induction of resistance of bacteria is not 
considered a major concern, since the mutation rate of phage keep up with the mutation rate 
of bacteria, sufficiently to maintain the effectiveness of phage therapy [46]. Furthermore, it 
is possible that the receptor used by the phage is a virulence determinant thus the loss of 
receptor would reduce the virulence of bacteria, then it would be easier for the host immune 
system to overcome the infection [14]. The use of cocktails of phages can also reduce the 
phage resistance [47,48]. 
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1.5. Antibacterial therapy  
In 1928, Alexander Fleming made accidentally an importante discovery for humanity, by 
observing the inibition of a bacterial culture of Staphylococcus aureus, by the action of a 
fungus, Penicillium notarum. Decades later, penicilin was the first antibiotic [49]. 
Most antibiotics can be classified due to its bactericidal or bacteriostatic activity[50]. 
However, usually the antibiotics are classified by its mechanism of action, which means, the 
target in bacteria where the antibacterial exerts its effect [51,52]. 
 
1.5.1.   Mechanism of action of antibiotics 
Nowadays, antibiotics are classified into five major groups based on its intracellular target 
and its mechanism of action (Figure 4)[53]. 
I. Cell wall synthesis inhibition (e.g. penicillin and derivatives, cephalosporins, 
carbapenems and glycopeptides). These compounds are more effective against 
infection by Gram positive bacteria, because of the cell wall that coats this type of 
bacteria. That kind of antibiotics have the peptidoglycan present on the cell wall 
as target, which means that prevent the synthesis of peptidoglycan, leading to 
weakening of the cell wall and lysing the bacterial cell [59-60]. 
II. Cell membrane disruption (polycationic peptide antibiotics like polymyxins). 
Some antibiotics have the capacity to interact with the membrane phospholipids 
of the bacteria cell, distorting the cell surface. Consequently, this disruption leads 
to leakage of cellular contents, thus killing the bacterium. Amtimicrobial agents 
that interfere with cytoplasmatic cell membrane are bactericidal[54]. 
III. Nucleic acid synthesis inhibition (quinolones, rifampicin and sulphonamides). 
Certain antibiotics interfere with DNA replication and transcription processes in 
microorganisms. This mechanism focuses in DNA gyrase and bacterial 
topoisomerase IV[51,52] 
IV. Protein synthesis inhibition (tetracycline, aminoglycosides, chloramphenicol 
and macrolides). In the ribosomes of bacteria is made the translation of the mRNA, 
allowing protein synthesis. The bacterial ribosomes have two subunits 30S and 
50S, differing from eukaryotic cells which have the subunits 40 S and 60s. 
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Antibiotics with this mechanism, bind to ribosomal subunits, interfering with a 
phase of the protein synthesis[51,52]. 
V. Metabolic process inhibition (e.g. sulfonamides). Folic acid is a vitamin which 
functions as a coenzyme in the synthesis of purines and pyrimidines. The bacteria 
need to synthesize this nutrient, because they cannot get it from the surroundings. 
Therefore, the antibiotics of this group act by mimicking the substrate of two 
enzymes (para-aminobenzoic acid, PABA and dihydrofolate, DMF) to produce 
the active form of folic acid, the tetrahydrofolic acid (THF)[51,52]. 
 
 
A. β-Lactams 
The β-lactams are antibiotics that have in their chemical composition a β-lactam ring 
[55]. Currently there are several types of β-lactam, which differ in structural position of the 
radical R. Penicillin G and V are natural, produced by fungus of the Penicillium genus, while 
some other β-lactam are semi-synthetic, being classified as amino-penicillins (ampicillin and 
amoxicillin), carboxi-penicillins (carbenicillin, ticarcillin, meticiclin, cloxacillin, 
flucloxacillin and oxacillin) and ureido-penicillins (azlocillin, mezlocillin, and piperacillin). 
Antibiotics classified as cephalosporins, carbapenems and monobactams are also β-lactams 
antibiotics.[56,57]. 
β-lactams antibiotics are antimicrobial agents that irreversibly inhibit the 
transpeptidase enzymes, whose function is to catalyze the transpeptidation reaction between 
the peptidoglycan chains of the bacterial cell wall. This enzyme activity leads to the 
formation of crosslinks between the peptide chains of the peptidoglycan structure, which is 
Figure 4: Classification of antibiotics by mechanism of action (Li, Collins, and Keene 2015) 
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capable of producing a significant rigid structure to protect the bacterial cell against changes 
in osmotic medium. The enzymes like transpeptidases and carboxiprptidases, named 
Penicillin- Binding- Proteins (PBPs) are the targets of the β-lactam antibiotics. All the β-
lactam antibiotics have bactericidal activity [56,58]. 
Ampicillin is an amino penicillin, an antibiotic with large spectrum, but it is 
particularly effective against Gram negative bacteria non producers of β-lactamases. The 
intensive and continuous use of these antibiotics leads to a reduction of the bacterial strains 
susceptible to ampicillin[58,59]. 
Piperacillin is an ureidopenicillin, an antibiotic with a very large action spectrum. It 
is very effective against both Gram negative and Gram positive bacteria.When compared to 
the natural penicillins and aminopenicillins, piperacillin is more slowly inactivated by β-
lactamases. 
 
B. Chloramphenicol 
Chloramphenicol is an inhibitor of protein synthesis, capable of binding to the 
peptidyltransferase centre of the 50S ribosomal unit, preventing the formation of peptid 
bonds. As a result of the binding process to enzymes, the antibiotic will prevent the 
elongation of the peptides. Chloramphenicol is a large-spectrum antibiotic against both 
Gram positive and Gram negative bacteria, with bacteriostatic characteristic. A few years 
ago, this antibiotic was used in human and veterinary medicine [13].  
 
C. Tetracycline 
Tetracycline is a bacteriostatic and broad-spectrum antibiotic quite effective against 
various aerobic and anaerobic bacteria, Gram positive and Gram negative[61,62]. 
Tetracyclines inhibits protein synthesis by binding to the 30S ribosome subunit, 
preventing the binding of aminoacyl-tRNA, causing misreading of the mRNA and blocking 
the addition of new amino acids. The release of proteins is also inhibited[57,61]. 
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D. Aminoglycosides 
Aminoglycoside antibiotics correspond to a group formed by two or more amino 
sugars connected by a glycosidic bond to a hexose amino. Most of aminoglycosides have a 
natural origin, but kanamycin is a semi-syntetic antibiotic[53]. 
The aminoglycosides exert their activity by binding irreversibly to the aminoacyl site 
of 16S ribosomal RNA (rRNA) within the 30S ribosomal subunit, leading to protein 
synthesis inhibition. Meanwhile, unlike other antibiotics with inhibition of the protein 
synthesis, aminoglycosides holds bactericidal activity[63]. 
The kanamycin was formerly used in the treatment of severe infections caused by 
Gram-negative, but currently this antibiotic has low clinical use due to its nephrotoxicity and 
ototoxicity and the bacterial resistance to this antibiotic [63,64]. 
 
E. Fluoroquinolones 
Fluoroquinolones are antimicrobial agents that are capable of interfere with the DNA 
synthesis by blocking the enzyme topoisomerase II and topoisomerase IV. The enzyme helps 
to roll up and unroll DNA durinf the DNA replication. DNA gyrase binds to DNA and 
introduces double stranded breaks that permits the DNA to unroll. Fluoroquinolones binds 
to the complex DNA gyrase- DNA and enable the broken DNA strands to be released into 
the cell, causing the cell death[65]. 
Ciprofloxacin is a Class II fluoroquinolone, with bactericidal activity. It has activity 
against a wide range of Gram-negative and Gram-positive microorganisms. Ciprofloxacin is 
slightly less active when at acidic pH. That antibiotic is used to treat several bacterial 
infections, namely UTI, gastroenteritis, nosocomial infections and sexually transmitted 
diseases[66]. 
 
1.5.2. Antibacterial resistance to antibiotics 
Antimicrobial agents are compounds that are capable to kill or inhibit bacterial 
growth[67]. Moreover, these compounds also act as selective forces for the bacterial 
evolution. Thus, the microorganisms adapted through different mechanisms, reducing the 
effectiveness of antimicrobial agents[68]. 
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However, beside the health impact, the antimicrobial resistances have a huge economic 
impact, because infections with multidrugs resistant microorganisms because multiresistant 
microorganisms require longer treatment, with higher costs and an increased risk of 
mortality[69]. 
The resistance of a bacterium to an antimicrobial drug can result from intrinsic or 
acquired mechanisms. The intrinsic mechanisms occur naturally in genes located on the 
bacterial chromosome and they are inherent to bacteria. These intrinsic mechanisms are 
related to the absence of the target or with the presence of low affinity targets, low cell 
permeability and also to multidrug efflux systems of multiresistant bacteria[70]. In the 
natural resistance, the bacteria are always resistant to the antimicrobial drug. 
Otherwise, in the acquired resistance, the bacteria are initially sensitive to a particular 
antibiotic, but due to various mechanisms it becomes resistant[71]. Acquired antimicrobial 
resistance can occur due to a mutation in the gene of the chromosome, consisting of the 
antibiotic target or by horizontal transfer of genes, specifically mobile genetic elements that 
are most likely to be transmitted[72].   
 Genes that confer bacterial resistance to antimicrobial drugs can be disseminated. 
With some exceptions, the intrinsic resistance and the resistance resulting from a mutation 
are resistance mechanisms that are unlikely to be transmitted[73]. The most frequent 
mechanism of acquisition of resistance genes corresponds to horizontal transfer, which may 
occur within the same strain or between different strains or even different bacterial 
genera[74]. There are three different mechanisms of horizontal gene transfer, transformation, 
conjugation and transduction Figure 5: 
I. Transformation- bacteria capture and incorporate segments of DNA from bacterial 
lysates, the resistance gene may be incorporated into the chromosome or plasmid 
in the recipient cell. The ability of bacteria to include extracellular genetic material 
and go through transformation is called competence [51]. 
II. Conjugation- process occurred as a result of direct contact of two bacterial cells, of 
the same kind or even of different species. In this mechanism exists the transfer of 
fragments of genetic material, usually through plasmids. That is dependent of the 
conjugative pili, that may or may not be present in the bacterial cell[75]. 
III. Transformation- mechanism of DNA acquisition by which non-viral DNA can be 
transfer mediated by bacteriophages. Although bacteriophages only can infect the 
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surrounding bacterial hosts, this mechanism has the advantage that transducing 
phages can the persistant during environmental conditions [74]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 After the bacteria gains resistant genes, they can use several biochemical types of 
antibiotic resistance, namely antibiotic inactivation (interference with cell wall synthesis), 
target modification (inhibition of protein synthesis), altered permeability (changes in outher 
membrane or formation of new membrane transporters) and efflux pumps Figure 6.  
Figure 6: Diagram representing the major machanisms of antibiotic resistance (Vranakis 2013) 
Figure 5: Horizontal gene transfer between bacteria (adapted from 
Furuya 2006) 
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1.5.3.  Escherichia coli genes of resistance to antibiotics 
 Escherichia coli is a bacterium capable of acquire multiple resistant genes to 
antibiotics, becoming a problem of public health. Over the years, most strains of E. coli have 
gain resistance to most antibiotics available. Some surveillance data show that resistance in 
E. coli is higther for antimicrobial agents that have been in use for longest time [13,67]. The 
principal genes responsible for antibiotic resistance found in E. coli strains are represented 
in Table 2[76–79]. 
 
Table 2: Major genes responsible for antibiotic resistances in strains of E. coli 
 
Antibiotic resistance  Gene 
Tetracycline  tetA; 
 tetB; 
Sulfamethoxazole-trimethoprim  Sul-1; 
 Sul-2; 
Penicillins + cephalosporins  blaTEM-1; 
 bla CTX-M; 
Oxapenicillins  OXA-1 
Chloramphenicol  cat I- IV 
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Chapter 2- Potential effects of bacteriophages and antibiotics to 
inactivate Escherichia coli 
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2.1. Introduction 
Escherichia coli is one of the most frequent causes of many common bacterial 
infections, including abdominal infections, urinary tract infections (UTI), enteric infections, 
pneumonia, bacteremia and meningitis[73]. This bacterium is the leading cause of both 
community-acquired and nosocomial UTI. Up to 50% of females eventually experience at 
least one episode of UTI. E coli causes 12 - 50% of nosocomial infections and 4% of cases 
of diarrheal disease [5,80]. 
After the discovery of antibiotics, in the decade of 30, their use increased exponentially, 
but microorganisms adapted through mechanisms of acquisition and transfer of resistance 
genes, reducing the effectiveness of these antibacterial agents. E. coli is capable of acquire 
multiple resistant genes to antibiotics, becoming a problem of public health [67]. 
Phage therapy, which uses lytic phages to inactivate bacteria, can be an alternative to 
antibiotics or used in combination with antibiotics to control infections. Several studies 
already shown that phages efficiently inactivate E. coli, even antibiotic resistant strains[81–
83]. 
A major concern regarding the use of phages to control infections is the emergency of 
phage-resistant mutant [82,84,85]. Resistance may result from the alteration or loss of the 
bacterial cell surface receptors; inhibition of phage DNA penetration; production of 
restriction endonucleases which degrade the phage DNA, clustered regularly interspaced 
short palindromic repeats (CRISPR) system, a widespread microbial response to by-pass the 
selective pressure exerted by phage infection, among others [86]. This limitation can be 
overcomed by the combined use of phages and antibiotics. Some studies shown a synergetic 
effect of the combined use of antibiotics and phages[87–89]. Zhang et al (2012), showed that 
the combination of phage SBW25φ2 and Kanamycin reduced the resistance evolution of a 
strain of Pseudomonas fluorescens SBW25 relatively to the antibiotic [88]. It has been stated 
that the decrease in bacterial resistance to phages and/or antibiotics in dual therapy is due to 
the fact that a strain non susceptible to one antimicrobial agent can be eliminated by the 
second one[84]. Another study performed by Comeau et al (2007), showed a synergism 
between the phage φMFP and several antibiotics, like aztreonam and cefixime against an 
uropathogenic E. coli (MFP). The combination of the phage with those antibiotics resulted 
in an increase of the phage lysis plaques production by the host bacterium. That result was 
not shown to antibiotics which the bacterium was inicially resistant, namely most penicillins 
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(e.g. piperacillin, ticarcillin and amoxicillin)[90]. The synergic effect between antibiotics 
and bacteriophages was also assessed by Verma et al (2009). On that study, the authors 
demonstrated a decrease in the bacterial density on the biofilm of Klebsiella pneumoniae 
B5055 with the lytic bacteriophage KPO1K and the conjugation of the phage with the 
antibiotic ciprofloxacin. Although the results of the treatments with the phage and the 
conjugation were equally effective, the combination had a decrease in the formation of 
resistant variants to that antibiotic [87]. 
It has also been shown that bacterial mutations induced by phages may lead to loss 
of pathogenic properties[91–93] and also decrease bacterial growth[94–96]. The loss of 
pathogenic properties and the decrease in the bacterial growth after phage exposure could be 
fitness cost which can contribute to their elimination from the environment faster than their 
wild-type parents. These results suggest that the remaining bacterial mutants maintained 
their viability in the presence of phages but their phenotypes and/or genotypes were affected 
[94–96]. 
The aim of this study was to evaluate the potential synergistic effect of phages and 
antibiotics in the inactivation of E. coli in order to control infections, namely UTI, and to 
reduce the development of resistance to phages and antibiotics. 
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2.2. Materials and methods 
 
2.2.1.  Bacterial strain and growth conditions 
The bacterial strain Escherichia coli ATCC 13706 was used as phage host. The E. coli  
strain was purchased from ATCC collection. The bacterial culture was stored in Tryptic Soy 
Agar (TSA; Liofilchem) at 4 ºC. Before each assay, one isolated colony was transferred to 
30 mL of Tryptic Soy Broth (TSB; Liofilchem) and grown overnight (16 - 18 hours) at 37 
ºC. Then, 300 µL of fresh culture was transferred to 30 mL of TSB and incubated overnight 
to reach the optical density (O.D. 600 nm) of 0.8, which correspond to about 109 cells per 
ml. All the procedures were done aseptically. 
 
2.2.2.   Phage selection and quantification 
A sewage water sample (station EEIS9 of SIMRIA Multi Sanitation System of Ria de 
Aveiro) was used to select the somatic bacteriophage of E. coli in a previous work by Pereira 
et al (2016). The authors have isolated two phages phT4A and ECA2 ( Pereira et al. 2016). 
An isolated and morphologically representative plaque of each phage was picked out with a 
Pasteur pipette, by aspiration, and was added to 50 mL of E. coli culture in the exponential 
growth phase. The mixture was incubated at 37 ºC for 6 - 8 hours. After that, the mixture 
was centrifuged at 13 000 G (Heraeus Megafuge 16R Centrifuge; Thermo Scientific) for 10 
min to remove non-infected bacteria and bacterial cell residues. The supernatant with the 
phage particles was stored at 4 ºC after the addition of 1% chloroform. 
The quantification of phages was determined, in duplicate, by the agar double layer 
technique, using TSA medium [98]. The plates were incubated upside-down at 37 ºC and 
after 18 h of incubation the number of lysis plaques was counted at the most convenient  
dillution (with around 30 - 300 lyses plaques per plate). The results were expressed as plaque 
forming units per mililitre (PFU/ mL). 
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2.2.3. Bacterial kill curves in PBS  
Bacterial inactivation was determined using the ECA2 phage suspension and the E. 
coli ATCC 13706 as host, at a MOI of 100. In order to obtain a MOI of 100, it was added 
2.5 µL of bacterial culture at a concentration of 108 CFU/mL and the phage suspension at a 
concentration of 108 CFP/mL to 30 mL of TSB in sterilized erlenmeyer. For each assay two 
control samples, the bacterial control (BC) and the phage control (PC) were included. The 
bacterial control was inoculated just with bacteria and without phage, and the phage control 
was inoculated with phage and without bacteria. The controls and test samples were 
incubated exactly in the same conditions, at 37 ºC. One mililiter of the test sample and of the 
bacterial and phage controls was collected at time zero and after 2, 4, 6 and 8 hours of 
incubation. The bacterial concentration was determined in duplicate, by pour plating, on 
TSA after an incubation period of 24 h at 37 ºC. The phage title was determinated, in 
duplicate, through the double agar layer method after an incubation period of 4 - 8 h at 37 
ºC. Three independent assays were done in different dates. 
 
2.2.4. Bacterial kill curves with phage and antibiotics in PBS 
In order to perform phage therapy with antibiotic, it was tested antibiotics with 
different mechanisms of action. Previously, it was done an Antimicrobial Susceptibility Test 
to guide the selection of the antibiotics to be used. It was selected the ampicillin (Applichem 
Panreac ITW companies) and piperacillin (Fluka Analytical) as β-lactams, kamanycin 
(Applichem Panreac ITW companies) as aminoglycoside, tetracycline (Sigma Life-Science), 
chloramphenicol (Applichem Panreac ITW companies) and the fluoroquinolone 
Ciprofloxacin (Sigma Life-Science). The phage therapy assay was performed as previously 
described, with the difference that was added an antibiotic control for each antibiotic used 
and a new test sample, added of phages and antibiotics. The antibiotic control (AC) was 
inoculated with bacteria and antibiotic at the MIC (according EUCAST 2015) for E. coli.. 
After 0, 2, 4, 6 and 8 h of incubation, aliquots of the test samples and of the controls were 
collected to quantify bacteria and phages. 
It was also performed a short assay, using the ciprofloxacin at MIC (0.5 mg/mL). The 
samples were collected at 0, 30, 60, 90 and 120 min. 
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2.2.5. Antimicrobial Susceptibility Tests  
The antimicrobial susceptibility tests were done according the EUCAST standards 
[100]. 
A bacterial culture with 5 hours of growth at 37 ° C (1.0 x 108 CFU / ml) was diluted 
1:100 in 0.85% saline solution to obtain a density of 0.5 MacFarland. After that, it was 
dipped a sterile cotton swab into the suspension and spreaded the inoculum over the entire 
surface of the plate of Muller-Hinton by swabbing in three directions. Then, the disks with 
antibiotics (ampicillin, kanamycin, piperacillin, tetracycline, chloramphenicol and 
ciprofloxacin) (OXOID) were placed at the plate and incubated inverted at 37 ºC for 16 – 20 
h. The diameters of inhibition zones were measured and the results were interpreted 
according information EUCAST (2015). 
 
2.2.6. Determination of the rate of emergence of phage-
resistant bacteria 
In order to determinate the frequency of phage-resistant bacteria the procedure 
described at Figure 7 was used. Ten isolated colonies from a plate with sensitive bacteria were 
selected and were inoculated into 5 mL of TSB medium, then, it was incubated at 37 ºC for 
24 h. One hundred µL of the 100 to 10-2 dilutions and 100 µL of the phage suspention was 
plated on TSA by the the double agar layer method. The plates were incubated until colonies 
of bacteria are seen (3 - 5 days). Simultaneously, it was spread 100 µL of the 10-5 to 10-7 
dilutions on TSA plates without phage. The plates were incubated for 24 h[93]. The 
previously prepared ten TSB cultures of bacteria were also used to determine the 
development of phage-resistant bacteria in the presence of antibiotics. An aliquot of 100 µL 
of culture was added to a new tube of TSB added of antibiotic at MIC. Then it was followed 
the same procedure (described above) (Figure 7) used to determine the development of 
phage-resistant bacteria in the presence of just phages [95]. 
The calculation of the frequency of mutants was done by dividing the number of 
resistant bacteria by the number of sensitive bacteria. This formula was used to calculate the 
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frequency of antibiotic resistant mutants, phage resistant mutants and the frequency of 
mutants for the mixture of phage and antibiotic. 
 
 
Figure 7: Design of the experimental work to test the emergence of bacterial resistances {adapted from 
(Haddix 2000) and (Filipov 2011) 
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2.2.7.  Determination of catalase and indol activity 
It was selected one colony of a phage-resistant bacteria, grown inside a lysis plaque of 
a spot test, which was inoculated in TSA medium. Simultaneously, was selected one 
bacterial colony without phage contact that was used as control. Then, physiological 
parameters were determined as described below.  
 
Catalase test 
The production of enzyme catalase was tested by placing three drops of the hydrogen 
peroxide (H2O2) reagent in microscope slides. After a bacterial colony was picked up with a 
stick and putted on the H2O2 drops. The presence or absence of the oxygen released was 
checked. The release of oxygen was considered as a positive test for catalase production. 
 
Indole test 
The production of indole due to the degradation of the acid tryptophan by 
tryptophanase enzyme was carriet out by inoculating the bacteria in TSA medium which 
contains tryptophan after incubation, 0.5 mL of Kovac´s reagent (aqueous solution of p-
dimethyl aminobenzaldehyde) were added to the TSA plate. The test was considered positive 
when a pink color was observed within 5 minutes.  
 
2.2.8. Bacterial kill curves in Urine 
Phage therapy experiments in urine were done with phage ECA2 and also with a phage 
cocktail with the phage ECA2 and other specific phage of E. coli, the phage cocktail 
phT4A/ECA2. Urine samples were provided by the laboratory of clinical analysis Avelab 
Aveiro (Portugal). Early urine samples were collected, using the Avelab Laboratory 
protocol, by midstream clean-catch technique after patient daily hygiene. The middle jact 
was collected directly into the sterile recipient. The urine samples presented a pH of 6, a 
density of 1.021 and did not contain proteins, epithelial cells or bacteria. The urine was 
previously centrifuged (13 000 x g, 10 minutes) and filtered through a 0.45 μm-pore-size 
polycarbonate membrane. Phage inactivation experiments were done at MOI of 100 for both 
phage ECA2 and phage cocktail phT4A/ECA2. Bacteria and phage controls were included 
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in all experiments. After 0, 2, 4, 6 and 8 h of incubation aliquots of the test samples and of 
the controls were collected to quantify bacteria and phages as described above. Three 
independent assays were done in different dates. 
 
2.2.9. Statistical analysis 
The program GraphPad Prism 6.01 was used for data analysis. The significance of 
differences in bacterial inactivation between the use of phages and the combination of phages 
and antibiotics was assessed using two-way ANOVA. The comparison between rate of 
phage-resistant bacteria in the presence and in the absence of antibiotics was assessed using 
one-way ANOVA. Normal distributions were assessed by the Kolmogorov-Smirnov test. 
Tukey's multiple comparison test was used for a pairwise comparison of the means. A value 
of p < 0.05 was considered significant. 
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2.3. Results 
 
2.3.1. Kill curves in PBS 
E. coli was challenged with the phage ECA2, in order to test its potencial as a 
therapeutic agent. The maximum of bacterial inactivation with this phage was 4.6 log 
CFU/ml at 2 h of treatment and, after 8 h, the bacterial inactivation was still significantly 
high (2.7 log), relatively to the bacterial control (ANOVA, p <0.05) (Figure 8A). 
Bacterial density in the BC increased 3.9 log (ANOVA, p < 0.05) during the 8 hours 
of treatment. 
No decrease of the phage survival (ANOVA, p > 0.05) was observed during the 
treatment, however, when the phage was incubated in the presence of its host, a significant 
increase in the phage concentration (1.2 log) was observed after the 8 hours of treatment, 
compared with the phage control (ANOVA, p < 0.05) (Figure 8 B).  
 
 
Figure 8: Inactivation of E. coli with phage ECA2 in PBS during 8 hours. (A)- Bacterial concentration: BC- 
bacterial control; B+P- bacteria plus phage. (B)- Phage concentration: PC-phage control; B+P bacteria plus 
phage. 
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2.3.2. Antibiotic test susceptibility 
Table  3: Antibiotic test susceptibility to Escherichia coli ATCC 13706 
Antibiotic Disk content 
(µg) 
Diameter (mm) Result 
Ampicillin 10 0 Resistant 
Kanamycin 30 0 Resistant 
Piperacillin 30 0 Resistant 
Tetracycline 15 18 Sensitive 
Chloramphenicol 30 27 Sensitive 
Ciprofloxacin 5 23 Sensitive 
 
Figure 9: Results of the Antibiotic Susceptibility test of the bacteria E. coli ATCC 13706. 
 
 The Antibiotic susceptibility test performed with the strain of E. coli ATCC 13706 
(Table  3) reveled that the bacterium is resistant to ampicillin, kanamycin and piperacillin. 
However, the bacterium showed susceptibility against ciprofloxacin, tetracycline and 
chlorampenicol. 
 
2.3.3. Kill curves in PBS with antibiotic 
 
2.3.3.1. Ampicillin 
Ampicillin was used at a MIC of 32 µg/mL in the sample with phage and antibiotic 
(B+P+A) and in the antibiotic control (AC). 
In the bacterial control cultures (BC and AC), E. coli reached a density of 8.9 log 
CFU/ml after 8 hours of incubation (Figure 10 A). However, there was no significant 
difference of the bacterial growth between the two bacterial controls (ANOVA, p > 
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0.05). In the presence of the phage, the number of viable bacteria decreased significantly, 
4.5 log, at 2 h of treatment (ANOVA, p < 0.05). Moreover, in the presence of the phage 
and ampicillin, the maximum bacterial inactivation was 4.4 log at 2 h of treatment 
(ANOVA, p < 0.05). Although both samples had high bacterial inactivation, it was not 
observed differences between the bacterial inactivation just with the phage and in the 
mix of the phage and the ampicillin (ANOVA, p > 0.05). 
No decrease in the phage survival was observed during the study period (ANOVA, 
p > 0.05). However, in the presence of its host, the phage title increased significantly 
(ANOVA, p < 0.05) for both samples (Figure 10 B). On the sample with bacteria and 
phage, the increase of the phage was 1.4 log, and on the sample with the mix of bacteria 
phage and antibiotic, the phage increase 1.2 log. Again there was no significantly 
differences between the results of the increase of the phage number (ANOVA, p > 0.05). 
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Figure 10:  Inactivation of E. coli with phage ECA2 and Ampicillin (MIC of 32 mg/L) in PBS during 8 
hours. (A)- Bacterial concentration: BC- bacterial control AC- Antibiotic control; B+P- bacteria plus 
phage, B+P+A- bacteria plus phage plus antibiotic. (B)- Phage concentration: PC-phage control; B+P 
bacteria plus phage; B+P+A- bacteria plus phage plus antibiotic. 
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2.3.3.2. Kanamycin 
The strain of E. coli used as a model for phage therapy was challeged with the phage 
ECA2 in one sample (B+P) and with the phage and kanamycin at MIC 32 mg/L (B+P+A). 
The maximum of bacterial inactivation for the sample B+P was 4.3 log CFU/ml at 2 h of 
treatment and, after 8 h, the bacterial inactivation was still significantly high (≈ 3 log), 
relatively to the bacterial control (ANOVA, p <0.05). For the sample with antibiotic 
(B+P+A), the maximum of bacterial inactivation was 4.6 log at 2 h and ≈2.9 log after 8 h of 
incubation (ANOVA, p <0.05). There was no significantly differences between between the 
results of bacterial inactivation of the samples B+P and B+P+A (ANOVA, p >0.05) (Figure 
11 A). The bacterial density increase during all the treatment for both bacterial controls 
(ANOVA, p <0.05), 3.8 log for the BC and 3.6 for the AC. The results of the bacterial growth 
of the the bacterial controls were similar (ANOVA, p >0.05). 
There were no differences in the phage survival during the study period (ANOVA, p 
>0.05). By contrast, in the presence of its host, the phage increased 1.1 log in the sample 
B+P and ≈1 log for the sample B+P+A (ANOVA, p <0.05) (Figure 11 B).  
There were no significantly differences between the results of the sample with the 
antibiotic kanamycin than the sample without antibiotic, just with phage (ANOVA, p > 
0.05). 
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Figure 11: Inactivation of E. coli with phage ECA2 and Kanamycin (MIC of 32 mg/L) in PBS 
during 8 hours. (A)- Bacterial concentration: BC- bacterial control AC- Antibiotic control; B+P- 
bacteria plus phage, B+P+A- bacteria plus phage plus antibiotic. (B)- Phage concentration: PC-
phage control; B+P bacteria plus phage; B+P+A- bacteria plus phage plus antibiotic. 
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2.3.3.3. Piperacillin 
In the bacterial control cultures (BC and AC), the bacteria increased 3.7 log of its 
density after 8 hours of incubation (Figure 12 A). However, the results of the bacterial growth 
in the bacterial control without piperacillin and with the presence of antibiotic were similar 
(ANOVA, p > 0.05). In presence of the phage, the number of viable bacteria decreased 
significantly, ≈ 4 log, at 2 h of treatment (ANOVA, p < 0.05). Moreover, in the presence of 
the phage and piperacillin, the maximum bacterial inactivation was 3.8 log at 2 h of treatment 
(ANOVA, p < 0.05). It was not observed differences between the bacterial inactivation just 
with the phage and in the mix of the phage and the antibiotic (ANOVA, p > 0.05).  
No decrease in the phage survival was observed during the study period (ANOVA, 
p > 0.05). However, in the presence of its host, the phage increased significantly (ANOVA, 
p < 0.05) for both samples (Figure 12 B). The phage increased ≈ 1 log for the sample B+P 
and 0.8 log for the sample B+P+A (ANOVA, p < 0.05). There were no differences in the 
results obtained between the samples B+P and B+P+A (ANOVA, p > 0.05). 
 
Figure 12: Inactivation of E. coli with phage ECA2 and Piperacillin (MIC of 16 mg/L) in PBS during 8 
hours. (A)- Bacterial concentration: BC- bacterial control AC- Antibiotic control; B+P- bacteria plus phage, 
B+P+A- bacteria plus phage plus antibiotic. (B)- Phage concentration: PC-phage control; B+P bacteria plus 
phage; B+P+A- bacteria plus phage plus antibiotic. 
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2.3.3.4. Tetracycline 
E. coli was challenged with the phage ECA2 (B+P) and with the mix of the phage 
ECA2 and the antibiotic Tetracycline at a MIC of 4 mg/ml. The maximum bacterial 
inactivation was observed at 2 h of treatment, for the sample B+P, with a bacterial decrease 
of 4 log (ANOVA, p < 0.05), relatively to the bacterial control. On the other hand, the sample 
with tetracycline (B+P+A) did not demonstrated alterations in the bacterial density during 
the study period (ANOVA, p > 0.05). Furthermore, the bacterial density of the sample 
B+P+A and the bacterial density of the antibiotic control had similar results during all the 
assay (ANOVA, p > 0.05) (Figure 13 A). The bacterial density of the BC without antibiotic 
shown an increase of 3.9 log at 8 h of incubation (ANOVA, p < 0.05). Those results were 
different from those obtained in AC (ANOVA, p < 0.05). 
No decrease was verified on survival of the phage in the PC and those results were 
similar of those obtained with the sample B+P+A (ANOVA, p > 0.05). However, in the 
sample B+P, an increase of the phage of ≈1 log (ANOVA, p < 0.05) was found (Figure 13 
B). 
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Figure 13: Inactivation of E. coli with phage ECA2 and Tetracycline (MIC of 4 mg/L) in PBS 
during 8 hours. (A)- Bacterial concentration: BC- bacterial control AC- Antibiotic control; 
B+P- bacteria plus phage, B+P+A- bacteria plus phage plus antibiotic. (B)- Phage 
concentration: PC-phage control; B+P bacteria plus phage; B+P+A- bacteria plus phage plus 
antibiotic 
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2.3.3.5. Chloramphenicol 
In the bacterial control, BC, E. coli reached a density of 8.8 log CFU/ml after 8 hours 
of incubation (Figure 14 A) (ANOVA p < 0.05). That result was significantly different from 
the obtained from the antibiotic control (ANOVA p <0.05), AC, where the bacterial density 
does not change during all the study period (ANOVA p >0.05).  
The maximum bacterial inactivation was observed at 2 h of treatment, in the sample 
without chloramphenicol (B+P), with a bacterial decrease of 4.1 log, comparatively to the 
bacterial control (ANOVA p < 0.05). Those bacterial inactivation was not obtained in the 
sample with antibiotic (B+P+A), where the bacterial density was stable during all the 8 h of 
treatment (ANOVA p >0.05). The phage control does not demonstrate a decrease in the 
phage survival 8 h (ANOVA p >0.05) and that result was similar to that obtained in the 
B+P+A (ANOVA p >0.05). On the other hand, the sample B+P had an increase of ≈1 log 
in the phage title (ANOVA p <0.05) (Figure 14 B). The results from both bacteria and phage 
concentrations were different between the two samples during all the treatment (ANOVA p 
<0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Inactivation of E. coli with phage ECA2 and Chloramphenicol (MIC of 8 mg/L) in PBS during 8 
hours. (A)- Bacterial concentration: BC- bacterial control AC- Antibiotic control; B+P- bacteria plus phage, 
B+P+A- bacteria plus phage plus antibiotic. (B)- Phage concentration: PC-phage control; B+P bacteria plus 
phage; B+P+A- bacteria plus phage plus antibiotic. 
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2.3.3.6. Ciprofloxacin 
In the bacterial control culture (BC), E. coli reached a density of 8.9 log CFU/ml after 
8 hours of incubation (Figure 15 A) and in the antibiotic control (AC) the bacterial density 
decreased 2.7 log after the 8 hours of treatment. It was shown a significant diference on the 
bacterial growth between the two bacterial controls (ANOVA, p < 0.05). In presence of the 
phage, the number of viable bacteria decreased significantly, 4.6 log, at 2 h of treatment 
(ANOVA, p < 0.05). Moreover, in the presence of the phage and ciprofloxacin, it was 
verified a maximum bacterial inactivation of 8.2 log after 6 h, relatively to the bacterial 
control (ANOVA, p < 0.05). Even though, the sample B+P+A shown a maximum bacterial 
inactivation, after 2 h of treatment, the sample already had a bacterial inactivation of 5.7 log 
(ANOVA, p < 0.05). Although both samples had high bacterial inactivation, the conjugation 
of the phage with ciprofloxacin increased the antimicrobial effect against E. coli (ANOVA, 
p < 0.05). Additionally, there was a decrease on the bacterial survival after the treatment 
between the sample with phage and ciprofloxacin and the sample with the phage alone 
(ANOVA, p < 0.05).  
No decrease in the phage survival was observed during the study period (ANOVA, p 
> 0.05). However, in the presence of its host, the phage title increased significantly 
(ANOVA, p < 0.05) for both samples (Figure 15 B). On the sample with bacteria and phage, 
the increase of the phage was 0.8 log, and on the sample with the mix of bacteria phage and 
antibiotic, the phage increase 0.7 log. There was no significant differences between the 
phage number values between the two samples (ANOVA, p > 0.05). 
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Figure 15: Inactivation of E. coli with phage ECA2 and Ciprofloxacin (MIC of 0.05 mg/L) in PBS during 
8 hours. (A)- Bacterial concentration: BC- bacterial control AC- Antibiotic control; B+P- bacteria plus 
phage, B+P+A- bacteria plus phage plus antibiotic. (B)- Phage concentration: PC-phage control; B+P 
bacteria plus phage; B+P+A- bacteria plus phage plus antibiotic. 
 
When the phage was tested with the antibiotic at MIC (0.5 mg/L), the bacterium was 
inactivated completely after 2 h, reaching an inactivation similar to that of the antibiotic 
alone after 2 h. Therefore, a short experiment of 2 h was done. The results show that density 
of the bacterial control (BC) increase during by 1.5 log CFU during the 120 min (Figure 16 
A). For in the antibiotic control (AC) the bacterial density decreased 4.9 log after the 120 
mins of treatment, relatively to the BC. A significant increase in the bacterial growth 
between the two bacterial controls (ANOVA, p < 0.05). In the presence of the phage, the 
bacterial density decreased 4.7 log after 120 min, but a significant decrease was observed 
after 90 min. The control of antibiotic and the sample with the mix of phage and 
ciprofloxacin did not show significant differences in the bacterial density among the assay 
(ANOVA, p > 0.05).  
No decrease in the phage survival was observed during the study period (ANOVA, 
p > 0.05) (Figure 16 B). However, in the sample B+P, the phage increased 0.9 log after the 2 
h. The increase was already observed at 90 min, the phage density was os 0.6 log. These 
results were significantly different from those obtained in the sample B+P+A (ANOVA, p 
> 0.05), which was stable during the 120 min period assay. 
 
6
6,5
7
7,5
8
8,5
0 2 4 6 8
Lo
g 
P
FU
/m
L
Time (hours)
PC
B+P
B+P+A
B 
 
 39 
 
 
 
 
 
2.3.4. Kill curves in Urine 
In order to test the properties of phages in the clinically relevant setting, the killing 
assays were repeated in urine. It was also tested a cocktail with two phages (ECA2/phT4A) 
to verify if the bacterial inactivation increase when compared with the inactivation using the 
single phage ECA2 suspension. The results of bacterial inactivation obtained with the phage 
ECA2 were significantly higher than the results obtained with the phage cocktail (ANOVA, 
p <0.05). The maximum bacterial inactivation was 4.3 log for the phage ECA2 and 3.5 log 
for the phage cocktail, both after 4 hours of treatment (ANOVA, p < 0.05) Although, after 2 
hours of incubation, the results of the bacterial inactivation between the phage ECA2 and 
cocktail were similar (≈1.4 log) (Figure 17 A). These results were different from those 
obtained in PBS, because in PBS the maximum amount of bacterial inactivation occurred at 
2 hours of treatment with about 4.6 log (ANOVA, p < 0.05). Also, the bacterial density in 
the BC increased 2.3 log (ANOVA, p < 0.05) during the 8 hours of treatment. 
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Figure 16: Inactivation of E. coli with phage ECA2 and Ciprofloxacin (MIC of 0.5 mg/L) in PBS during 
120 min. (A)- Bacterial concentration: BC- bacterial control AC- Antibiotic control; B+P- bacteria plus 
phage, B+P+A- bacteria plus phage plus antibiotic. (B)- Phage concentration: PC-phage control; B+P 
bacteria plus phage; B+P+A- bacteria plus phage plus antibiotic. 
 
 40 
 
The phage survival was constant during study period for both phage controls, the single 
phage and the cocktail and the results obtained between them were similar (ANOVA, p > 
0.05). In the presence of the host, the phage increase significantly, by 1 log and 0.7 log to 
the phage ECA2 and the phage cocktail respectively (ANOVA, p < 0.05). These results were 
not different between phages throughout the entire treatment (ANOVA, p > 0.05) (Figure 17 
B).  
 
 
 
2.3.5. Kill curves with ciprofloxacin in Urine 
It was selected the antibiotic ciprofloxacin to be used in conjugation with the phage 
ECA2 in urine, due to the best results obtained in PBS. The best results of bacterial 
inactivation were obtained with the sample B+P+A, for which a bacterial inactivation of ≈8 
log was observed after 6 h of treatment. Even though, after 4 h of treatment, the bacterial 
density was already low (0.15 log). The reduction was significantly different between the 
samples B+P and B+P+A (ANOVA, p < 0.05) (Figure 18 A). For the sample with the phage 
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Figure 17: Inactivation of E. coli with phage ECA2 and the cocktail of two phages ECA2/T4 in human urine 
during 8 hours. (A)- Bacterial concentration: BC- bacterial control; B+ECA2- bacteria plus phage ECA2, 
B+(ECA2/T4)- bacteria plus cocktail (ECA27T4). (B)- Phage concentration: C ECA2-phage control; 
C(ECA2/T4)- cocktail control;  B+ECA2 bacteria plus phage ECA2; B+(ECA2/T4)- bacteria plus phage 
cocktail 
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(B+P) a bacterial decrease of 5.2 log, relatively to the bacterial control (ANOVA, p < 0.05) 
was observed. These results were similar to those obtained in PBS (ANOVA, p > 0.05).  
 The bacterial control (BC) showed a bacterial increase of 2.9 log and the antibiotic 
control had a bacterial increase of 1.4 log during the 8 hours assay. Those results of the 
bacterial controls were significantly different (ANOVA, p < 0.05). However, the results 
obtained in the antibiotic control were significantly different from those obtained in PBS 
(ANOVA, p > 0.05). 
The phage survival was constant during study period for phage control (ANOVA, p > 
0.05). In the presence of the host, the phage increase significantly, by 0.6 log and 0.7 log for 
the sample B+P+A and the sample B+P, respectively (ANOVA, p < 0.05). These results 
were not different throughout the entire treatment (ANOVA, p > 0.05) (Figure 18 B).  
 
 
 
Figure 18: Inactivation of E. coli with phage ECA2 and Ciprofloxacin (MIC of 0.05 mg/L) in Urine during 8 
hours. (A)- Bacterial concentration: BC- bacterial control AC- Antibiotic control; B+P- bacteria plus phage, 
B+P+A- bacteria plus phage plus antibiotic. (B)- Phage concentration: PC-phage control; B+P bacteria plus 
phage; B+P+A- bacteria plus phage plus antibiotic. 
 
 
 
0
2
4
6
8
10
0 2 4 6 8
Lo
g 
C
FU
/m
L
Time (hours)
BC
AC
B+P
B+P+A
A
6,5
7
7,5
8
8,5
0 2 4 6 8
Lo
g 
P
FU
/m
L
Time (hours)
PC
B+P
B+P+A
B
 42 
 
2.3.6. Determination of the emergence of bacterial mutants  
It was tested the development of phage resistant mutants of E. coli against the phage 
ECA2, using antibiotics for which the bacterium was initially resistant (ampicillin, 
kanamycin and piperacillin) and for the antibiotic for which the bacterium was sensible, 
ciprofloxacin.  
The bacterium showed different rates of phage-resistant mutants for the phage ECA2 
and for the mixture of the phage with antibiotics (Table 4), but these differences were not 
significant (ANOVA, p > 0.05) for the antibiotics ampicillin, kanamycin and piperacillin. 
 However, for the mixture of ECA2 and ciprofloxacin a significant decrease in the 
phage-resistant mutants, 0.9 log, relatively to the sample with ECA2 (ANOVA, p < 0.05) 
was observed. 
The samples with ampicillin, kanamycin and piperacillin without phage contact, showed 
a frequency of mutants against those antibiotics of ≈1 (ANOVA, p > 0.05). In contrast, the 
results of the bacterial resistance to ciprofloxacin were significant lower to those of the 
bacteria resistance to the phage. That difference was about 0.8 log (ANOVA, p < 0.05). 
Also the phage-resistant bacterial colonies were smaller than those of the control 
without added phage and have grown slower, during 4 days of incubation. In the control, 
colonies were visible after 24 h of incubation in similar conditions. The samples were tested 
in TSB medium and urine and the results obtained were similar (ANOVA, p > 0.05). 
 
Table 4: Frequency of mutants of Escherichia coli ATCC 13706 to the phage ECA2, antibibiotics and to the 
conjugation of both. 
Sample Frequency 
of 
antibiotic-
mutans 
(CFU/ml) 
Sample Frequency of 
phage-
mutans 
(CFU/ml) 
Sample Frequency of 
phage and 
antibiotic 
mutans 
(CFU/ml) 
Ampicillin 1.023158±0.24 Phage 
ECA2 
5.02402±1.47x 
10-6 
 
Ampicillin + 
ECA2 
1.17±1.03x 10-5 
Kanamycin 1.012104±0.27 Phage 
ECA2 
5.02402±1.47x 
10-6 
Kanamycin
+EC2 
1.4±1.13x 10-5 
Piperacillin 1.181003±0.39 Phage 
ECA2 
5.02402±1.47x 
10-6 
Piperacillin
+EC2 
2.3±1.1x 10-5 
Ciprofloxacin 2.745± 
0.16x10-4 
Phage 
ECA2 
5.02402±1.47x 
10-6 
Ciprofloxaci
n +ECA2 
2.4±1.5x10-7 
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2.3.7.  Growth of bacterial resistant mutants 
The results obtained for bacterial growth without phage and ampicillin (sensible 
bacteria), bacteria resistant to ampicillin, bacteria resistant to the phage ECA2 and bacterial 
resistant to the mixture of ampicillin and ECA2 was determined during 96 hours of 
incubation (Figure 19 I). In the samples with the bacteria without the phage and antibiotic 
and bacteria resistant to ampicillin the number after 24 h was similar , ≈9 log, and was stable 
during the 4 days. On the other hand, the samples with phage showed a lower number, 
≈3.5log, which grew slower then those observed in samples without phages. For kanamycin 
and piperacillin, a similar profile of variation was observed (data not shown). 
When, ciprofloxacin was tested, the sample with antibiotic showed a higher number 
of bacterial resistant mutants than sample with the phage ECA2 after 24 h. After 24 h, the 
number of bacterial resistant mutants to ciprofloxacin does not changed during the next 3 
days, the number of bacterial resistant to the phage changed during the following 3 days 
(Figure 19 II). For samples with ciprofloxacin and phage ECA2 also an increase of the 
CFU/mL was observed during the incubation period but the increase was significantly lower 
than that of the bacteria which was grown in the presence of the phage and of the bacteria 
alone. 
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 (I) 
(II) 
Figure 19: Bacterial concentration of resistant mutants to phage, antibiotics and the misture of phage and 
antibiotic and of sensitive bacteria during 96 h of incubation.  
(A)- sensitive bacteria; (B)-bacteria resistant to ampicillin 32 µg/mL; (C)-bacteria resistant to ciprofloxacin 
0.05 µg/mL; (D)- bacteria resistant to phage ECA2; (E)- bacteria resistant to phage ECA2 plus ampicillin 32 
µg/mL; (F)-bacteria resistant to phage ECA2 plus ciprofloxacin 0.05 µg/mL. 
 
2.3.8. Physiological characteristics of E. coli before and 
after phage treatment. 
 The results of the catalase and indol tests after phage treatment were both positive as 
the results for the cultures without phage treatment.  
E. coli before treatment with the phage was resistant ampicillin (0 mm), kanamycin 
(0 mm) and piperacillin (0 mm) and sensitive to ciprofloxacin (23 mm). This pattern of 
variation does not changed after phage addition both in PBS and in urine.  
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2.4. Discussion 
The emergence of antibiotic resistant bacterial pathogens is a serious concern 
worldwide and has directed more research interest to alternative therapies. A promising 
alternative to antibiotics is the use of bacteriophages. Nowadays, several controlled studies 
conducted in vitro [94,95,101,102], ex vivo [104,105] and in animal models [96,106–110]; 
have demonstrated that phage therapy has great potential to control infections caused by 
bacteria [95,110]. However, although these studies show support for the efficacy of phage 
therapy, the development of phage-resistant mutants is a general shortcoming 
[95,97,97,111,112]. 
This shortcoming can be, however, overcome by the use of phage cocktails 
[14,45,48,105,113–116]. Moreover, recent works suggest that positive interactions have 
been observed between lytic phages and antibiotics in controlling bacterial pathogens both 
in vitro and in vivo [87–89,117,118]. However, little is known about the interactions process 
of phages and antibiotics in combined therapies namely when 1) bacteria is resistant to 
antibiotics, 2) the antibiotic is bacteriostatic, 3) the effects of antibiotic doses and 4) how 
compare the emergence of phage-resistant and antibiotic-resistant mutants, aspects that we 
have tried to lighten in this study.  
The results of this study showed that 1) phage and antibiotic combinations could 
result in high synergistic effect in the inactivation of bacteria, even when the antibiotic is 
used at sublethal doses (below MIC), but 2) the efficacy of the combination depends on the 
antibiotic resistance status of the targeted bacteria to the employed antibiotic and of the 
antibiotic type (bactericide or bacteriostatic), 3) causing the same or less resistance than 
phages and antibiotics applied alone and that 4) the development of resistance to phages is 
lower than that observed relatively to antibiotics. 
Combination therapies are already used in the treatment of diverse microbial illnesses 
such as tuberculosis, malaria or AIDS. For the successful of these combined therapies it is 
essential that each agent has different bacterial targets, such as in the case of phages and 
antibiotics associations, contributing thus to an increased inactivation. In this study, bacterial 
density reduction by the combined action of the tested phage and antibiotic was higher than 
that caused either by phage and antibiotic applied individually but only when the bacterium 
was sensitive to a bactericidal antibiotic, the ciprofloxacin. The maximal inactivation of E. 
coli by the combined action of the phages and the ciprofloxacin at a concentration 10 times 
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lower than MIC (0.05 µg mL-1) was of 8.2 log after 6 h, but the bacterial reduction by the 
phage and antibiotic applied individually was 4.6 and 2.7 log, respectively, after 2 and 8 h 
of treatment. The E. coli inactivation by the mixture after 2 h was already of 5.7 log. When 
the phage was tested with the antibiotic at MIC, the bacterium was inactivated efficiently 
after 1 h, reaching an inactivation similar to that of the antibiotic alone after the same time. 
However, when phages are used alone, after 1.5 h of treatment it was already possible to 
detect phage particles in the sample (phage concentration at 3.3 x 107 PFU/mL at 1.5h), but 
when the phage is used with ciprofloxacin, the increase in phage particles occurred only after 
2 h (phage concentration: 7.8 x 106 PFU/mL at 1.5 h). At MIC, the ciprofloxacin affected 
the protein synthesis, which avoid to the replication of the phage by the host bacteria. 
Consequently, no synergistic effect can occurred at MIC. Our in vitro experimental results 
with ciprofloxacin and phages confirm previous findings [90,119] showing that sublethal 
doses of antibiotics produce a phage-antibiotic synergistic effect, reducing the bacterial 
number but only when bacteria are sensitive to the used antibiotics. The same results were 
observed when the ciprofloxacin at MIC was tested. Besides, the combination of antibiotics 
and phages could also reduce the doses of phages. It has been shown that low multiplicities 
of phage infection (MOI) can be effective to inactivate bacteria in vitro and in vivo [120,121]. 
So, it would be important to test the effect of the use of the combined effect of antibiotics 
and phages at different MOI. Decreasing both antibiotic and phage concentrations would 
decrease the release of bacterial toxins after lysis, namely in case of Gram negative bacterial 
inactivation, reducing the frequency of septic shock situations.  
The increase in bacterial inactivation was not observed for the combined therapy 
when the tested antibiotic was bacteriostatic or when the bacterium was resistant to the tested 
antibiotics independently of their mechanisms of action/bacterial target sites. Thus, our 
results are not in accordance with previous studies in which is mentioned that the synergistic 
effects of phages and antibiotics are relatively insensitive to antibiotic type [122]. This 
profile was only observed when the bacterium was resistant to the tested antibiotic. 
The E. coli strain tested in this study was also sensitive to the tetracycline and 
chloramphenicol, which are bacteriostatic antibiotics. However, with these two antibiotics 
no increase in bacterial inactivation was observed when they were used in combination with 
phages. These antibiotics only avoid bacterial growth, not causing bacterial reduction, 
avoiding also phage replication. Both antibiotics inhibit the bacterial protein synthesis 
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preventing viral replication by the host. However, a study with tetracycline and a phage 
showed a synergistic effect in the inactivation of Burkholderia cepacia [123]. Tetracycline 
was used at 2.5 mg/L to 40 mg/L, showing synergistic effect in bacterial inactivation at ½ 
MIC and an increase in the number of produced phages at 2X and 4X MIC (MIC of 10 mg/L 
for Burkholderia strain K56-2). In our study, tetracycline was tested at MIC concentration 
for E. coli (4 mg/L). These differences suggest that the synergistic effect can vary with the 
bacteria. Further studies using different bacteria are necessary to confirm this hypothesis. 
Similarly, linezolid applied with phage caused also a higher reduction than the antibacterial 
alone on Staphylococcus aureus density [124]. The linezolid was applied at 25 mg/kg, a 
concentration higher [125] than MIC (4 mg/L) and in different conditions than those used in 
our study, in vivo inactivation of a Gram positive bacterium. 
When phages were tested in the presence of antibiotics for which the E. coli was 
resistant, no synergistic effect of the combined therapy was observed. For the bactericidal 
antibiotics piperacillin and ampicillin, drugs that affect the cell wall synthesis, and for the 
bactericidal antibiotic kanamycin, which inhibits the protein synthesis, the inactivation was 
similar to that observed when the phage was used alone. Also, for the three antibiotics the 
combined therapy the number of produced phages was also similar to that when phages were 
tested individually. This means that when bacteria are resistant to antibiotics, independently 
of the mechanism of action of the antibiotic, and consequently, independently of the affected 
targeted bacterial site, no synergistic effect of the two treatments decrease the bacterial 
density. To the best of our knowledge there are no other studies using the combination of 
phages with antibiotics for which bacteria are resistant. However, there are some studies 
showing that some bacteria, such as the Burkholderia cepacia complex, which possess high 
levels of innate antimicrobial resistance, when treated with the combination of phages and 
antibiotics for which these bacterial species are sensitive, increase the reduction of bacterial 
density when compared with that using phages or antibiotics alone [123]. Overall, although 
antibiotics belonging to different classes and having different mechanisms of action cause a 
synergistic effect on bacterial inactivation when combined with phages [126], if the bacteria 
are resistant to the used antibiotics no synergistic effect is observed. 
Several studies have reported that the synergistic effect of phages and antibiotics may 
be due to the stimulation of bacterial production of phages by the antibiotic 
[90,117,119,123,127]. However, in this study, when the combination of phages and 
 48 
 
antibiotic ciprofloxacin, at a concentration 10 x lower than MIC, was used to inactivate the 
E. coli, the number of phages produced was similar to that observed when phages were tested 
without antibiotic. Further studies, using different antibiotic concentrations and different 
bacteria and even other phages, are necessary to clarify the reason for this different behavior. 
It has been shown that the combination of antibiotics with phages is an alternative 
that cannot only be effective at reducing bacterial numbers but also to contribute to managing 
resistance levels. However, this view has only been discussed with regard to antibiotic 
resistance and not to control phage-mutant emergence. In our study we compared not only 
the resistance of the bacteria to the four antibiotics tested with and without phages, but also 
the resistance to the phages in the presence and in the absence of antibiotics. Relatively to 
the antibiotics, and as already indicated by some authors the results of this study showed that 
for the four antibiotics tested, independently of their type and mechanism of action, the 
phages limit the emergence of antibiotic resistant variants in combined treatments. The 
resistance to the four antibiotics was lower than that observed for the combination of phage 
and antibiotic (range 1.023158 to 2.745 x 10-4 CFU/mL without phages and range 2.3 x 10-
5 to 2.4 x 10-7 with phages). Although, some authors detected that phage-antibiotic 
combinations can cause the same resistance than either antimicrobial introduced in isolation 
to our knowledge none study indicated that resistance to antibiotics in the presence of phages 
was higher than that developed without phages[87,88,122,128]. Thus, contrary to the 
suggestion that double-resistant bacteria would be strongly selected when antibiotic 
cocktails is used [129], antibiotic and phage combinations indicate the opposite effect. 
Additionally, in this study, the resistance to the antibiotics alone was higher than that 
observed when the phages were used alone (1.023158 to 2.745 x 10-4 CFU/mL for antibiotic 
and range 5.02402 x 10-6 CFU/mL for phages). This means that although some phage-
mutants can emerge after phage treatment, the frequency of resistance would be lower than 
that caused by the conventional antibiotic worldwide used. However, more studies using 
other bacteria and phages are needed to confirm this pattern of resistance development. 
These results confirm the findings of other authors, like Verma et al (2009), which compared 
the resistance to antibiotics in the presence of phages with that observed with phages and 
without antibiotics[87]. 
Our findings showed also that the addition of antibiotics during phage treatment can 
also control the phage-mutant emergence. When ciprofloxacin was added at a sublethal 
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concentration (concentration 10x lower than MIC) together with the phage, the rate of 
emergence of phage-mutants was lower than that observed when the antibiotic was not used. 
However, this reduction in the phage-mutants development was not detected for the other 
three antibiotics tested with the phage. For these, the emergency of phage-mutants was 
similar to that observed without antibiotic addition. Overall, the resistance of phage-mutants 
in the presence of antibiotics was the same or less than when phages were tested alone. This 
conclusion was confirmed by the antibiogram results obtained after treatment with the 
combination of phages and antibiotics and with phages alone. After treatment with the 
combination and with the phage alone, the bacterium was sensitive to the ciprofloxaxin, 
tetraciclin and chlorophenicol but continue resistant to the ampicillin, kanamycin and 
piperacillin. 
Our results are in accordance with the suggestion that simultaneous resistance to 
antibiotics and phages entails larger costs than to either antibacterial agent separately. In 
fact, previous results of our group have shown that phage-resistant mutants after successive 
cultivation in culture medium change the pattern of resistance to the phage. After 3-5 
successive streak-plating steps of phage-mutants isolates on solid medium, a clear lysis 
plaques can be observed after the spot test for different sets of bacteria and phages [95–
97,110] However, when the efficiency of infection is determined, using the double agar layer 
method, for these phage-resistant mutants no increase in the efficiency of infection was 
detected. Similarly, when infrared spectroscopy was used to study the surface of the these 
phage-resistant mutants relatively to sensitive cells to the phages, spectral differences 
between resistant mutants and the sensitive cells were clear, being the differences more 
relevant for peaks associated to amide I and amide II from proteins [95]. It is a possibility 
that the proteins present in the external surface of bacterial resistant cells, which can be used 
as receptors for phages, are someway modified, thus leading to the observed resistance. 
Nonetheless, colonies of phage-resistant mutants were smaller than colonies formed by the 
non-phage added control and were visible only after 3 days of incubation. In the non-phage 
added control, bacterial colonies were visible after 24 hour of incubation. These results 
suggest that the remaining bacterial mutants (forming small size colonies and showing slow 
growth) maintained their viability in the presence of phages but their phenotypes were 
affected. Similar results were already observed in other studies [91,92,97]. These decrease 
in the bacterial growth after phage exposure could be fitness cost which can contribute to 
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their elimination from the environment faster than their wild-type parents. However, in this 
study the two physiological bacterial characteristics, catalase and indole after phage 
treatment were similar to those of non-treated bacteria. Further studies using other bacterial 
characteristics are needed to understand the interaction phage-bacteria and, consequently, to 
evaluate the fitness of the phage-resistant mutants. 
In order to test if phage therapy could be used to control UTI caused by E. coli, a 
bacterium responsible for more than half of the UTI worldwide [10], the phage ECA2 and a 
phage cocktails with other phage specific for E. coli (the phage phT4A), the effectiveness of 
phage treatment was also tested in urine samples. The phage ECA2 alone and in the cocktail 
was effective to inactivate E. coli in urine. The phages survived in the urine, maintained their 
concentration in the absence of the host, and significantly increased their titer in the presence 
of the bacterium during the study period. Phages effectiveness to inactivate the E. coli in 
urine was similar to that observed in the experiment in PBS, 5 log against to 4.6 log after, 
but the maximal bacterial inactivation occurred later, after 4 h, than in PBS (maximal 
inactivation at 2 h of treatment). When phage therapy was done in the presence of 
ciprofloxacin at sublethal concentration, a synergistic effect, as observed in PBS, was 
detected, and the bacterium was inactivated to the detection limit of the method (reduction 
of 8 log) after 6 h of treatment. Also, after 4 h of treatment, almost all bacteria were 
inactivated. When the antibiotic was tested alone, the bacterial inactivation was lower than 
in PBS. This can be due to the degradation of the ciprofloxacin at low pH values. In fact, the 
FDA (2014) [130] showed the ciprofloxacin is not stable at low values of pH. However, in 
the presence of the phages, this effect was not observed, which suggest that ciprofloxacin 
when used in combination with phages could be used at lower concentrations. 
The high bacterial inactivation efficiency with phages combined with a higher 
inactivation in the presence of antibiotic at a sublethal concentration (inactivation to the 
detection limit of the method) and the long periods of phage survival, even in urine samples, 
paves the way for depth studies, especially in vivo studies, to control urinary tract infection 
and to overcome the development of resistances by E. coli, the bacterium most frequently 
isolated in UTI at the community level and at hospital settings. Although the viability of the 
phages was not affected by the low pH of urine, the stability of the antibiotic was depressed, 
even though the efficiency of the combined phage-antibiotic therapy has not been affected, 
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the results of this study highlight the importance of testing the efficacy of new approaches 
to inactivate bacteria in clinically relevant setting. 
 
 
2.5. Future perpectives 
After this work, it will be interesting to evaluate: 
 The synergistic effect between the phage and other antibiotics which the bacteria is 
sensible (test MIC and subletal doses of antibiotic); 
 Isolate bacteria from UTI patients and apply phage therapy; 
 Test the synergism phage-antibiotics for other bacteria and phages; 
 Evaluate the synergistic mechanisms between phages and antibiotics; 
 Understand the resistance mechanisms of phages; 
 Evaluate the effect of the mix of phage therapy with antibiotics on the virulence 
factors of bacteria; 
 Apply phage therapy with antibiotics in animal models, like mice and Galleri 
mellonella. 
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